NASDAQ:PRPOPrecipio Stock Price, Forecast & News

Precipio's stock was trading at $1.17 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, PRPO stock has decreased by 17.9% and is now trading at $0.96. View which stocks have been most impacted by Coronavirus.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Precipio in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Precipio.

Precipio is scheduled to release its next quarterly earnings announcement on Friday, August 14th 2020. View our earnings forecast for Precipio.

Precipio (NASDAQ:PRPO) posted its earnings results on Thursday, August, 23rd. The biotechnology company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of $1.93 by $2.08. The biotechnology company earned $0.82 million during the quarter. Precipio had a negative return on equity of 109.58% and a negative net margin of 407.60%. View Precipio's earnings history.

Precipio shares reverse split before market open on Tuesday, June 6th 2017. The 1-30 reverse split was announced on Thursday, May 25th 2017. The number of shares owned by shareholders was adjusted after the market closes on Monday, June 5th 2017. An investor that had 100 shares of Precipio stock prior to the reverse split would have 3 shares after the split.

1 brokerages have issued twelve-month target prices for Precipio's shares. Their forecasts range from $2.00 to $2.00. On average, they expect Precipio's stock price to reach $2.00 in the next twelve months. This suggests a possible upside of 108.3% from the stock's current price. View analysts' price targets for Precipio.

Media coverage about PRPO stock has trended extremely negative this week, according to InfoTrie Sentiment Analysis. The research group scores the sentiment of media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Precipio earned a media sentiment score of -4.6 on InfoTrie's scale. They also assigned news headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View the latest news aboutPrecipio.

Some companies that are related to Precipio include HTG Molecular Diagnostics (HTGM), BioNano Genomics (BNGO), Aethlon Medical (AEMD), Arrayit (ARYC), Scientific Industries (SCND), Pressure Biosciences (PBIO) and PositiveID (PSID). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Precipio investors own include Portola Pharmaceuticals (PTLA), Biocept (BIOC), Inpixon (INPX), Jaguar Health (JAGX), MannKind (MNKD), Cellectar Biosciences (CLRB), Inovio Pharmaceuticals (INO), NovaBay Pharmaceuticals (NBY), NovaBay Pharmaceuticals (NBY) and Tonix Pharmaceuticals (TNXP).

Precipio trades on the NASDAQ under the ticker symbol "PRPO."

Shares of PRPO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of PRPO stock can currently be purchased for approximately $0.96.

Precipio has a market capitalization of $10.69 million and generates $3.13 million in revenue each year. Precipio employs 42 workers across the globe.

The official website for Precipio is www.precipiodx.com.

Precipio's mailing address is 4 Science Park, New Haven CT, 06511. The biotechnology company can be reached via phone at 203-787-7888 or via email at [email protected]